悦康药业：子公司YKYY018雾化吸入剂获国家药监局临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical announced that its wholly-owned subsidiary, Yuyuan Kechuang, has received approval from the National Medical Products Administration for two clinical trial approval notices for the YKYY018 aerosol inhalation agent, aimed at post-exposure prevention and treatment of RSV infection [1] Group 1 - The product is an internationally original membrane fusion inhibitor drug, which has obtained core patent authorization and global exclusive rights [1] - The company will initiate Phase I clinical trials for the YKYY018 aerosol inhalation agent [1] - The product has also received clinical trial approval from the U.S. FDA [1] Group 2 - The company highlights the long development cycle, multiple stages, and high risks associated with drug research and development [1] - Investors are reminded to be cautious regarding the inherent risks in the pharmaceutical development process [1]